As reported by Cheruiyot et al. [25], a small molecule inhibitor that targets SMG1, which activates the NMD pathway by phosphorylating UPF1, was used to investigate the effect of NMD inhibition as a potential approach in cancer treatment. Here, PLA1A is linked to cancer.